| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
XXII Stock Overview
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries.
22nd Century Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.95 |
| 52 Week High | US$4.17 |
| 52 Week Low | US$1.42 |
| Beta | 1.6 |
| 1 Month Change | -9.95% |
| 3 Month Change | 29.67% |
| 1 Year Change | -48.55% |
| 3 Year Change | 2.37% |
| 5 Year Change | -10.78% |
| Change since IPO | 49.61% |
Recent News & Updates
22nd Century GAAP EPS of -$0.06 in-line, revenue of $14.5M beats by $3.21M
22nd Century press release (NASDAQ:XXII): Q2 GAAP EPS of -$0.06 in-line. Revenue of $14.5M (+72.6% Y/Y) beats by $3.21M. The increase was due to increased contract manufacturing volumes as well as the addition of GVB Biopharma revenue for approximately half of the second quarter.
22nd Century Group launches $35M securities offering
22nd Century Group (NASDAQ:XXII) has announced a $35M share and warrant offering priced above market under Nasdaq rules. The offering will consist of 17,073,175 shares of common stock issued at $2.05/share. The company also agreed to offer unregistered warrants to purchase up to 17,073,175 shares of common stock; warrants are immediately exercisable at $2.05/share and will expire five years following the date of issuance. Gross proceeds are expected to be $35M; net proceeds will be used for expansion and expedite the launch of XXII's VLN reduced nicotine content tobacco cigarettes in additional markets, R&D expenses, procurement and development of additional IP rights, working capital and general corporate purposes. The proceeds will not be used to repay indebtedness or fund the operations of the company’s subsidiary, GVB Biopharma. Offering is expected to close on July 25, 2022.
Shareholder Returns
| XXII | US Tobacco | US Market | |
|---|---|---|---|
| 7D | 8.7% | 2.3% | 0.3% |
| 1Y | -48.5% | -55.7% | -13.5% |
Return vs Industry: XXII exceeded the US Tobacco industry which returned -53.9% over the past year.
Return vs Market: XXII underperformed the US Market which returned -13% over the past year.
Price Volatility
| XXII volatility | |
|---|---|
| XXII Average Weekly Movement | 15.4% |
| Tobacco Industry Average Movement | 15.4% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XXII is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: XXII's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 76 | Jim Mish | https://www.xxiicentury.com |
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications.
22nd Century Group, Inc. Fundamentals Summary
| XXII fundamental statistics | |
|---|---|
| Market Cap | US$417.66m |
| Earnings (TTM) | -US$36.50m |
| Revenue (TTM) | US$33.19m |
12.6x
P/S Ratio-11.4x
P/E RatioIs XXII overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XXII income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Aug 09, 2022
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 5.67% |
| Net Profit Margin | -109.97% |
| Debt/Equity Ratio | 0% |
How did XXII perform over the long term?
See historical performance and comparison